Navigation Links
Ovarian cancer in relationship with Hormone therapy

A major US study has found that women who have taken postmenopausal oestrogens for ten years or more are at substantially greater risk of fatal ovarian cancer.

The risk persists for many years after therapy is discontinued, researchers from the American Cancer Society report// in the Journal of the American Medical Association.The study followed 201,681 postmenopausal women from 1982 to 1996 and found ERT (oestrogen replacement therapy) increased the risk and this persisted for up to 29 years after women stopped using it.

Twenty two percent of the women in the study had used ERT, including 11,024 who were users at the start of the study (baseline users) and 35,236 who were former users. A total of 944 ovarian cancer deaths were recorded in the 14 year study until December 1996.

Researchers found the risk of death was approximately doubled in women who had used oestrogens for ten or more years within the 15 years prior to enrolment. Annual age-adjusted ovarian cancer death rates per 100,000 women were 64.4 for baseline users with 10 or more years of use, 38.3 for former users with 10 or more years of use, and 26.4 for never users.

Women who were using ERT at baseline had 51 percent higher death rates from ovarian cancer than those who never used ERT. Among former oestrogen users, the risk was 16 percent higher - a slight, but not significant increase. However, women who had used ERT for less than 10 years had no greater risk.

Postmenopausal oestrogen is already known to increase the risk of endometrial and breast cancer when used for a long time, but until this study, the effect of postmenopausal oestrogen use on ovarian cancer had not established.


'"/>




Page: 1

Related medicine news :

1. Exercise lowers Risk of Ovarian Cancer
2. Gene Mutation Causes Ovarian Failure
3. Ovarian Cancer Screening Questioned
4. Thawed Ovarian Transplant
5. The Benefits Of Chemotherapy For Women With Ovarian Cancer
6. Progesterone Found To Increase Ovarian Cancer Risk
7. Developmental Origins of Polycystic Ovarian Syndrome
8. Polycystic Ovarian Syndrome(PCOS) linked to Diabetes
9. Ovarian cancer risk reduced by regular exercise
10. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
11. Genetic Profile To Predict Ovarian Cancer Prognosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: